Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics

Journal of Clinical Oncology

Volumn 20, Issue 8, 2002, Pages 2171-2180

  Carducci, Michael A ^a   Nelson, Joel B ^a   Bowling, M Kathy ^a   Rogers, Theresa ^a   Eisenberger, Mario A ^a   Sinibaldi, Victoria ^a   Donehower, Ross ^a   Leahy, Terri L ^a   Carr, Robert A ^a   Isaacson, Jeffrey D ^a   Janus, Todd J ^a   Andre, Amy ^a   Hosmane, Balakrishna S ^a   Padley, Robert J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ADULT; AGED; ANALGESIA; ARTICLE; ASTHENIA; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EDEMA; FEMALE; HEADACHE; HEMODILUTION; HISTOLOGY; HUMAN; MALE; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHINITIS; STEADY STATE; WEIGHT GAIN;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PYRROLIDINES; RECEPTORS, ENDOTHELIN; SALVAGE THERAPY;

EID: 0037089676     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.028     Document Type: Article

References (42)

1. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology
2. Pharmacological characterization of A-127722: An orally active and highly potent ETA-selective receptor antagonist
3. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
4. Endothelins as autocrine regulators of tumor cell growth
5. Growth regulatory properties of endothelins
6. The endothelin system and its potential as a therapeutic target in cardiovascular disease
7. Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells
8. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer
9. The role of endothelins in proliferation, apoptosis, and angiogenesis
10. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion
11. Contribution of endogenous generation of endothelin-1 to basal vascular tone
12. Endothelin induces vasoconstriction in the bone vasculature in vitro: An effect mediated by a single receptor population
13. Endothelin-1, -2 and -3 directly and big-endothelin-1 indirectly elicit an abdominal constriction response in mice
14. Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve
15. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade
16. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate
17. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression
18. Expression of endothelin receptor A associated with prostate cancer progression
19. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: Evidence for an autocrine role in tumor growth
20. Paracrine regulation of ovarian cancer by endothelin
21. Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: New potential targets for anticancer therapy
22. Expression and localization of endothelin-1 and endothelin receptors in human meningiomas: Evidence for a role in tumoral growth
23. Correlation of endothelin-1 and transforming growth factor b1 with malignancy and vascularity in human gliomas
24. Endothelin messenger RNA and receptors are differentially expressed in cultured human breast epithelial and stromal cells
25. Abundant expression of immunoreactive endothelin 1 in mammary phyllodes tumor: Possible paracrine role of endothelin 1 in the growth of stromal cells in phyllodes tumor
26. Endothelin attenuates apoptosis in human smooth muscle cells
27. Osteoblastic bone metastases: Tumor-produced endothelin-1 mediates new bone formation via the endothelin A receptor
28. Inhibition of tumor growth and angiogenesis by ABT 627 an endothelin receptor A antagonist in ovarian carcinoma xenografts
29. Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective antagonist in humans
30. Development of the Wisconsin brief pain questionnaire to assess the pain in cancer and other diseases
31. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales
32. Determination of atrasentan by high performance chromatography with fluorescence detection in human plasma
33. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
34. Short-term oral endothelin receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
35. Multicenter double blind placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure. Results of the REACH-1 trials
36. Endothelin A receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
37. The role of nitric oxide in migraine pain, in Pain 1996: An updated Review IASP Refresher Course on Pain Management
38. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy
39. Effects of enrasentan, a nonselective endothelin receptor antagonist, in class II-III heart failure: Results of the enrasentan cooperative randomized (ENCOR) evaluation
40. Multiple dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist